At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Bertrand Coiffier (Centre Hospitalier Lyon-Sud, Pierre-Benite, France) discusses the final analysis of the RO-CHOP phase Ib/II study of the histone deacetylase inhibitor, romidepsin, in association with cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone (CHOP) in previously untreated patients with peripheral T-cell lymphoma.